newsfilter
← Latest News
GlobeNewswire·

Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's Disease

– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying ("AIM") Biologicals as a potential therapeutic treatment option for Parkinson's